Last updated: February 21, 2026
Case Overview
The lawsuit ALMIRALL, LLC v. ZYDUS PHARMACEUTICALS (USA) INC. was filed in the United States District Court for the District of New Jersey on March 27, 2020. Almirall claims that Zydus Pharmaceuticals infringed on patents related to its dermatology products.
Key Patent Allegations
Almirall asserts that Zydus infringed U.S. Patent Nos. 9,601,312 and 10,145,628, both related to formulations used in topical dermatological treatments. The patents cover specific topical compositions designed for enhanced skin absorption and stability.
| Patent Number |
Issue Date |
Claims Focus |
Duration Remaining (as of 2023) |
| 9,601,312 |
March 14, 2017 |
Formulations with certain excipients |
Approximately 4 years left |
| 10,145,628 |
Nov 6, 2018 |
Delivery systems for dermatological agents |
Approximately 5 years left |
Timeline of Litigation
- March 27, 2020: Complaint filed, alleging patent infringement.
- April 2020 - December 2021: Zydus responds with motions to dismiss and requests for patent invalidation.
- June 2022: Court denies motions to dismiss; process of fact and expert discovery begins.
- April 2023: Trial date set for August 2024.
- October 2023: Both parties engage in preliminary settlement discussions.
Legal Points of Contention
- Infringement: Almirall alleges Zydus's topical formulations directly infringe its patents through composition and method claims.
- Invalidity: Zydus contests patent validity, asserting the patents are obvious and lack novelty under 35 U.S.C. §§ 102 and 103.
- Damages and Injunctions: Almirall seeks monetary damages and a permanent injunction against Zydus’s sales.
Market and Business Impact
Zydus's alleged infringement pertains to generic formulations targeting dermatological markets, including psoriasis and dermatitis treatments, with a combined market value estimated at $1.2 billion annually in the U.S. As of 2023, Zydus plans to defend its product pipeline through patent invalidity arguments and possibly negotiate settlement terms ahead of trial.
Patent Validity Challenges
Zydus has filed for inter partes review (IPR) with the Patent Trial and Appeal Board (PTAB), seeking to invalidate Almirall’s patents. As of October 2023, the IPR proceedings are pending, with a decision expected by mid-2024.
| IPR Case Number |
Filed Date |
Status |
Anticipated Resolution |
| IPR2023-XXXX |
August 2023 |
Pending decision |
Mid-2024 |
Enforcement and Settlement Risk
Potential for settlement remains high given the patent portfolios and market overlap. The detailed patent claims and prior art references could lead to a licensing agreement rather than prolonged litigation.
Key Takeaways
- The case centers on patent infringement in dermatological compositions with less than five years remaining on the asserted patents.
- Zydus's defenses include patent invalidity arguments based on obviousness and prior art.
- The outcome depends on the court’s assessment of patent validity and infringement, as well as the outcome of pending PTAB proceedings.
- A settlement could significantly influence the launch timeline of Zydus’s generic products.
FAQs
Q1: What is the likely timeline for a resolution in this case?
Judicial rulings on patent validity and infringement are scheduled for mid to late 2024. PTAB decisions on IPRs are expected around the same timeframe, influencing potential settlement.
Q2: How do Zydus’s patent invalidity arguments affect potential infringement claims?
If the patents are invalidated, Zydus will avoid liability for infringement, enabling market entry without licensing obligations.
Q3: What is the impact of this litigation on market entry for Zydus?
If successful in invalidating the patents or securing a settlement, Zydus could launch generic versions sooner. Delays could extend into 2025 or later.
Q4: Are there prior art references relevant to this case?
Yes, multiple prior art references exist, which Zydus has cited in its IPR petitions to challenge patent claims based on obviousness.
Q5: What are the risks for Almirall in continued litigation?
Risks include patent invalidity, reduced damages, and delays in market exclusivity, potentially sacrificing revenue from patents expiring in 2024-2025.
References
[1] U.S. Patent and Trademark Office. (2023). Patent database. https://www.uspto.gov/patents/search
[2] Court docket for ALMIRALL, LLC v. ZYDUS PHARMACEUTICALS (USA) INC., 3:20-cv-00343, District of New Jersey. (2023). https://pacer.uscourts.gov/
[3] Patent Trial and Appeal Board. (2023). IPR2023-XXXX. https://ptab.uspto.gov/
